The QcrB inhibitors TB47 and telacebec do not potentiate the activity of clofazimine in mycobacterium abscessus

Ria Sorayah; Garret C. Moraski; Daniel Barkan; Kevin Pethe

doi:10.1128/AAC.00964-21

The QcrB inhibitors TB47 and telacebec do not potentiate the activity of clofazimine in mycobacterium abscessus

Ria Sorayah, Garret C. Moraski, Daniel Barkan, Kevin Pethe^*

^*Corresponding author for this work

The Koret School of Veterinary Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

The antituberculosis drug telacebec is ineffective against Mycobacterium abscessus. A recent study suggested that TB47, a telacebec analogue, potentiated the efficacy of clofazimine against M. abscessus. Here, we report that TB47 not only is ineffective against M. abscessus in vitro but also does not potentiate the activity of clofazimine.

Original language	American English
Article number	e00964-21
Journal	Antimicrobial Agents and Chemotherapy
Volume	65
Issue number	12
DOIs	https://doi.org/10.1128/AAC.00964-21
State	Published - Dec 2021

Bibliographical note

Funding Information:
This work was supported in part by the Lee Kong Chian School of Medicine, Nanyang Technological University (Singapore), Start-Up Grant (K.P.) and the National Research Foundation (Singapore) under its Investigatorship Program (grant NRF-NRFI06-2020-0004). R.S. is supported by a scholarship from the NTU Institute for Health Technologies, Interdisciplinary Graduate Program, Nanyang Technological University. We thank Sung Jae Shin for the gift of the clinical isolates.

Publisher Copyright:
Copyright © 2021 American Society for Microbiology. All Rights Reserved.

Keywords

Cytochrome bcc:aa
Nontuberculous mycobacteria
Oxidative phosphorylation
Q203
Terminal oxidase
Tuberculosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/AAC.00964-21

Cite this

@article{0338ff45602949ac988bb56e8214dad9,

title = "The QcrB inhibitors TB47 and telacebec do not potentiate the activity of clofazimine in mycobacterium abscessus",

abstract = "The antituberculosis drug telacebec is ineffective against Mycobacterium abscessus. A recent study suggested that TB47, a telacebec analogue, potentiated the efficacy of clofazimine against M. abscessus. Here, we report that TB47 not only is ineffective against M. abscessus in vitro but also does not potentiate the activity of clofazimine.",

keywords = "Cytochrome bcc:aa, Nontuberculous mycobacteria, Oxidative phosphorylation, Q203, Terminal oxidase, Tuberculosis",

author = "Ria Sorayah and Moraski, {Garret C.} and Daniel Barkan and Kevin Pethe",

note = "Funding Information: This work was supported in part by the Lee Kong Chian School of Medicine, Nanyang Technological University (Singapore), Start-Up Grant (K.P.) and the National Research Foundation (Singapore) under its Investigatorship Program (grant NRF-NRFI06-2020-0004). R.S. is supported by a scholarship from the NTU Institute for Health Technologies, Interdisciplinary Graduate Program, Nanyang Technological University. We thank Sung Jae Shin for the gift of the clinical isolates. Publisher Copyright: Copyright {\textcopyright} 2021 American Society for Microbiology. All Rights Reserved.",

year = "2021",

month = dec,

doi = "10.1128/AAC.00964-21",

language = "American English",

volume = "65",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "12",

}

TY - JOUR

T1 - The QcrB inhibitors TB47 and telacebec do not potentiate the activity of clofazimine in mycobacterium abscessus

AU - Sorayah, Ria

AU - Moraski, Garret C.

AU - Barkan, Daniel

AU - Pethe, Kevin

N1 - Funding Information: This work was supported in part by the Lee Kong Chian School of Medicine, Nanyang Technological University (Singapore), Start-Up Grant (K.P.) and the National Research Foundation (Singapore) under its Investigatorship Program (grant NRF-NRFI06-2020-0004). R.S. is supported by a scholarship from the NTU Institute for Health Technologies, Interdisciplinary Graduate Program, Nanyang Technological University. We thank Sung Jae Shin for the gift of the clinical isolates. Publisher Copyright: Copyright © 2021 American Society for Microbiology. All Rights Reserved.

PY - 2021/12

Y1 - 2021/12

N2 - The antituberculosis drug telacebec is ineffective against Mycobacterium abscessus. A recent study suggested that TB47, a telacebec analogue, potentiated the efficacy of clofazimine against M. abscessus. Here, we report that TB47 not only is ineffective against M. abscessus in vitro but also does not potentiate the activity of clofazimine.

AB - The antituberculosis drug telacebec is ineffective against Mycobacterium abscessus. A recent study suggested that TB47, a telacebec analogue, potentiated the efficacy of clofazimine against M. abscessus. Here, we report that TB47 not only is ineffective against M. abscessus in vitro but also does not potentiate the activity of clofazimine.

KW - Cytochrome bcc:aa

KW - Nontuberculous mycobacteria

KW - Oxidative phosphorylation

KW - Q203

KW - Terminal oxidase

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85119367530&partnerID=8YFLogxK

U2 - 10.1128/AAC.00964-21

DO - 10.1128/AAC.00964-21

M3 - Article

C2 - 34543090

AN - SCOPUS:85119367530

SN - 0066-4804

VL - 65

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 12

M1 - e00964-21

ER -

The QcrB inhibitors TB47 and telacebec do not potentiate the activity of clofazimine in mycobacterium abscessus

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this